Atara Biotherapeutics (ATRA)
(Delayed Data from NSDQ)
$0.69 USD
-0.01 (-1.40%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.69 0.00 (0.00%) 6:16 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
ATRA 0.69 -0.01(-1.40%)
Will ATRA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ATRA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ATRA
What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings?
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
ATRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates
Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why
Atara (ATRA) Up 11% on Regulatory Update From Blood Cancer Study
Other News for ATRA
Commit To Buy Atara Biotherapeutics At $0.50, Earn 24.2% Annualized Using Options
Commit To Purchase Atara Biotherapeutics At $0.50, Earn 22.3% Annualized Using Options
12 Health Care Stocks Moving In Monday's After-Market Session
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA) and Embecta Corporation (EMBC)